{"id":723,"date":"2026-09-01T15:21:54","date_gmt":"2026-09-01T15:21:54","guid":{"rendered":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/"},"modified":"2026-09-01T15:32:23","modified_gmt":"2026-09-01T15:32:23","slug":"tirzepatide-surmount-1-2539-adults-72-weeks","status":"publish","type":"case_study","link":"https:\/\/nhdbio.com\/fr\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/","title":{"rendered":"Tirzepatide SURMOUNT-1\u00a0:\u00a0adultes 2,539 sur des semaines 72"},"content":{"rendered":"<h2>Pourquoi SURMOUNT-1 est une \u00e9tude d'ancrage utile<\/h2>\n<p>SURMOUNT-1 est un vaste essai randomis\u00e9 de phase 3 avec un groupe placebo et des crit\u00e8res d'\u00e9valuation coprimaires pr\u00e9d\u00e9finis. Cela soutient donc une discussion sur les preuves cliniques plus forte que les affirmations m\u00e9canistes ou les observations incontr\u00f4l\u00e9es. Le document rapporte \u00e9galement l\u2019ensemble complet des groupes de doses randomis\u00e9s plut\u00f4t qu\u2019un nombre choisi de mani\u00e8re s\u00e9lective.<\/p>\n<h2>Population et param\u00e8tres<\/h2>\n<p>L'essai a recrut\u00e9 des adultes atteints de BMI d'au moins 30, ou d'au moins 27 avec une complication li\u00e9e au poids, et a exclu le diab\u00e8te. Les participants ont \u00e9t\u00e9 randomis\u00e9s \u00e0 parts \u00e9gales dans trois groupes tirz\u00e9patide ou placebo. L'estimation du sch\u00e9ma th\u00e9rapeutique \u00e9valuait les r\u00e9sultats ind\u00e9pendamment de l'arr\u00eat du traitement dans la population en intention de traiter.<\/p>\n<h2>R\u00e9sultats en contexte<\/h2>\n<p>Les trois groupes tirz\u00e9patide diff\u00e9raient du placebo en ce qui concerne les param\u00e8tres de poids rapport\u00e9s. L'article signale \u00e9galement les \u00e9v\u00e9nements ind\u00e9sirables gastro-intestinaux comme les plus courants, g\u00e9n\u00e9ralement lors d'une escalade, et fournit des pourcentages d'arr\u00eat pour chaque groupe randomis\u00e9. Garder ces d\u00e9nominateurs et donn\u00e9es sur les \u00e9v\u00e9nements ind\u00e9sirables visibles emp\u00eache un r\u00e9sum\u00e9 de l\u2019efficacit\u00e9 uniquement.<\/p>\n<div class=\"pfm-case-callout\"><strong>Limite de comparaison\u00a0:<\/strong> SURMOUNT-1 n\u2019\u00e9tait pas un essai sur le r\u00e9tatrutide et ne peut pas fournir un classement direct Retatrutide versus Tirzepatide. Les pourcentages d\u2019essais crois\u00e9s proviennent de diff\u00e9rents protocoles et \u00e9tapes de d\u00e9veloppement.<\/div>\n<h2>Distinction des m\u00e9dicaments finis<\/h2>\n<p>Les r\u00e9sultats cliniques d'un m\u00e9dicament fini examin\u00e9 par l'organisme de r\u00e9glementation ne peuvent pas \u00eatre transf\u00e9r\u00e9s \u00e0 un mat\u00e9riau partageant un nom mais ne poss\u00e9dant pas la m\u00eame formulation, le m\u00eame syst\u00e8me d'administration, les m\u00eames sp\u00e9cifications de lib\u00e9ration et les m\u00eames contr\u00f4les de qualit\u00e9. Cette distinction fait partie du dossier de preuve et non une note de bas de page.<\/p>","protected":false},"excerpt":{"rendered":"<p>Une lecture structur\u00e9e de l'essai SURMOUNT-1 Phase 3, pr\u00e9servant la conception randomis\u00e9e, les r\u00e9sultats en quatre groupes, les donn\u00e9es d'arr\u00eat et la distinction entre un m\u00e9dicament fini approuv\u00e9 et le mat\u00e9riel destin\u00e9 \u00e0 la recherche.<\/p>","protected":false},"author":0,"featured_media":851,"template":"","class_list":["post-723","case_study","type-case_study","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Tirzepatide SURMOUNT-1 Trial: 2,539 Adults<\/title>\n<meta name=\"description\" content=\"A structured reading of the SURMOUNT-1 Phase 3 trial, preserving the randomized design, four-group results, discontinuation data and the distinction between an approved finished drug and research-use material.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/fr\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tirzepatide SURMOUNT-1: 2,539 Adults Over 72 Weeks\" \/>\n<meta property=\"og:description\" content=\"A structured reading of the SURMOUNT-1 Phase 3 trial, preserving the randomized design, four-group results, discontinuation data and the distinction between an approved finished drug and research-use material.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/fr\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-01T15:32:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/tirzepatide-surmount-1-editorial-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1672\" \/>\n\t<meta property=\"og:image:height\" content=\"941\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/\",\"name\":\"Tirzepatide SURMOUNT-1 Trial: 2,539 Adults\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/tirzepatide-surmount-1-editorial-v2.webp\",\"datePublished\":\"2026-09-01T15:21:54+00:00\",\"dateModified\":\"2026-09-01T15:32:23+00:00\",\"description\":\"A structured reading of the SURMOUNT-1 Phase 3 trial, preserving the randomized design, four-group results, discontinuation data and the distinction between an approved finished drug and research-use material.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/tirzepatide-surmount-1-editorial-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/tirzepatide-surmount-1-editorial-v2.webp\",\"width\":1672,\"height\":941,\"caption\":\"Editorial research illustration; not a photograph of trial participants or an actual study site.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u6848\u4f8b\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Tirzepatide SURMOUNT-1: 2,539 Adults Over 72 Weeks\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Essai Tirzepatide SURMOUNT-1\u00a0:\u00a0adultes 2,539","description":"Une lecture structur\u00e9e de l'essai SURMOUNT-1 Phase 3, pr\u00e9servant la conception randomis\u00e9e, les r\u00e9sultats en quatre groupes, les donn\u00e9es d'arr\u00eat et la distinction entre un m\u00e9dicament fini approuv\u00e9 et le mat\u00e9riel destin\u00e9 \u00e0 la recherche.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/fr\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/","og_locale":"fr_FR","og_type":"article","og_title":"Tirzepatide SURMOUNT-1: 2,539 Adults Over 72 Weeks","og_description":"A structured reading of the SURMOUNT-1 Phase 3 trial, preserving the randomized design, four-group results, discontinuation data and the distinction between an approved finished drug and research-use material.","og_url":"https:\/\/nhdbio.com\/fr\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/","og_site_name":"NHD","article_modified_time":"2026-09-01T15:32:23+00:00","og_image":[{"width":1672,"height":941,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/tirzepatide-surmount-1-editorial-v2.webp","type":"image\/webp"}],"twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/","url":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/","name":"Essai Tirzepatide SURMOUNT-1\u00a0:\u00a0adultes 2,539","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/tirzepatide-surmount-1-editorial-v2.webp","datePublished":"2026-09-01T15:21:54+00:00","dateModified":"2026-09-01T15:32:23+00:00","description":"Une lecture structur\u00e9e de l'essai SURMOUNT-1 Phase 3, pr\u00e9servant la conception randomis\u00e9e, les r\u00e9sultats en quatre groupes, les donn\u00e9es d'arr\u00eat et la distinction entre un m\u00e9dicament fini approuv\u00e9 et le mat\u00e9riel destin\u00e9 \u00e0 la recherche.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/tirzepatide-surmount-1-editorial-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/tirzepatide-surmount-1-editorial-v2.webp","width":1672,"height":941,"caption":"Editorial research illustration; not a photograph of trial participants or an actual study site."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"\u6848\u4f8b","item":"https:\/\/nhdbio.com\/case-studies\/"},{"@type":"ListItem","position":3,"name":"Tirzepatide SURMOUNT-1: 2,539 Adults Over 72 Weeks"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Mati\u00e8res premi\u00e8res peptidiques et synth\u00e8se sur mesure","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/case_study\/723","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/case_study"}],"about":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/types\/case_study"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/case_study\/723\/revisions"}],"predecessor-version":[{"id":728,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/case_study\/723\/revisions\/728"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media\/851"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media?parent=723"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}